Neuromuscular blocking agents' differential bronchoconstrictive potential in guinea pig airways

Anesthesiology

Volumn 106, Issue 4, 2007, Pages 763-772

  Jooste, Edmund ^b   Zhang, Yi ^b   Emala, Charles W ^a  

^a Howard Hughes Medical Institute   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ATROPINE; CISATRACURIUM; GALLAMINE; HISTAMINE; MEPYRAMINE; MIVACURIUM; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; RAPACURONIUM; ROCURONIUM; UNCLASSIFIED DRUG; VECURONIUM;

AIRWAY; AIRWAY PRESSURE; ARTICLE; ATTENUATION; BRONCHOSPASM; DRUG POTENTIATION; GUINEA PIG; HEART RATE; HISTAMINE RELEASE; IN VITRO STUDY; IN VIVO STUDY; LUNG INFLATION; MALE; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; VAGUS NERVE;

EID: 34147190266     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/01.anes.0000264763.48920.c9     Document Type: Article

References (60)

1. Jooste E, Klafter F, Hirshman CA, Emala CW: A mechanism for rapacuronium-induced bronchospasm: M2 muscarinic receptor antagonism. ANESTHESIOLOGY 2003; 98:906-11
2. Jooste E, Zhang Y, Emala CW: Rapacuronium preferentially antagonizes the function of M2 versus M3 muscarinic receptors in guinea pig airway smooth muscle. ANESTHESIOLOGY 2005; 102:117-24
3. Struckmann N, Schwering S, Wiegand S, Gschnell A, Yamada M, Kummer W, Wess J, Haberberger RV: Role of muscarinic receptor subtypes in the constriction of peripheral airways: Studies on receptor-deficient mice. Mol Pharmacol 2003; 64:1444-51
4. Lee AM, Jacoby DB, Fryer AD: Selective muscarinic receptor antagonists for airway diseases. Curr Opin Pharmacol 2001; 1:223-9
5. Fryer AD, Maclagan J: Pancuronium and gallamine are antagonists for pre- and post-junctional muscarinic receptors in the guinea pig lung. Naunyn Schmiedebergs Arch Pharmacol 1987; 335:367-71
6. 3 muscarinic receptors in guinea pig lung and heart. ANESTHESIOLOGY 1996; 84:155-61
7. Hashimoto S, Shibata O, Tsuda A, Iwanaga S, Makita T, Sumikawa K: Steroidal muscle relaxants attenuate the contractile and phosphatidylinositol responses of rat trachea. Res Commun Mol Pathol Pharmacol 1998; 100:255-63
8. Jooste EH, Sharma A, Zhang Y, Emala CW: Rapacuronium augments acetylcholine-induced bronchoconstriction via positive allosteric interactions at the M3 muscarinic receptor. ANESTHESIOLOGY 2005; 103:1195-203
9. Ellis J, Seidenberg M: Interactions of alcuronium, TMB-8, and other allosteric ligands with muscarinic acetylcholine receptors: Studies with chimeric receptors. Mol Pharmacol 2000; 58:1451-60
10. Lazareno S, Popham A, Birdsall NJ: Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol 2002; 62:1492-505
11. Fryer AD, Maclagan J: Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1984; 83:973-8
12. Faulkner D, Fryer AD, Maclagan J: Postganglionic muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1986; 88:181-7
13. Fryer AD, Wills-Karp M: Dysfunction of M2-muscarinic receptors in pulmonary parasympathetic nerves after antigen challenge. J Appl Physiol 1991; 71:2255-61
14. Kahn RM, Okanlami OA, Jacoby DB, Fryer AD: Viral infection induces dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lung. J Clin Invest 1996; 98:299-307
15. Costello RW, Evans CM, Yost BL, Belmonte KE, Gleich GJ, Jacoby DB, Fryer AD: Antigen-induced hyperreactivity to histamine: Role of the vagus nerves and eosinophils. Am J Physiol 1999; 276:L709-14
16. Costello RW, Schofield BH, Kephart GM, Gleich GJ, Jacoby DB, Fryer AD: Localization of eosinophils to airway nerves and effect on neuronal M2 muscarinic receptor function. Am J Physiol 1997; 273:L93-103
17. 2 mediated bronchoconstriction in the anesthetized guinea pig. Eur J Pharmacol 1982; 80:19-27
18. Hirshman CA, Downes H: Experimental asthma in animals, Bronchial Asthma: Mechanisms and Therapeutics, 3rd edition. Edited by Weiss EW, Segal MS, Stein M. Boston, Little, Brown, 1993, p 38
19. Dixon WE, Brody TG: Contributions to the physiology of the lungs: I. The bronchial muscles and their innervation and the action of drugs upon them. J Physiol (Lond) 1903; 29:97-173
20. Blaber LC, Fryer AD, Maclagan J: Neuronal muscarinic receptors attenuate vagally-induced contraction of feline bronchial smooth muscle. Br J Pharmacol 1985; 86:723-8
21. Danser AH, van den ER, Lorenz RR, Flavahan NA, Vanhoutte PM: Prejunctional beta 1-adrenoceptors inhibit cholinergic transmission in canine bronchi. J Appl Physiol 1987; 62:785-90
22. Handley DA, Senanayake CH, Dutczak W, Benovic JL, Walle T, Penn RB, Wilkinson HS, Tanoury GJ, Andersson RG, Johansson F, Morley J: Biological actions of formoterol isomers. Pulm Pharmacol Ther 2002; 15:135-45
23. Vettermann J, Beck KC, Lindahl SG, Brichant JF, Rehder K: Actions of enflurane, isoflurane, vecuronium, atracurium, and pancuronium on pulmonary resistance in dogs. ANESTHESIOLOGY 1988; 69:688-95
24. Diefenbach C, Mellinghoff H: The clinical pharmacology of mivacurium [in German]. Anaesthesist 1997; 46:385-8
25. Scholz J, von KG, Peters K, Kycia B, Schulte am EJ: Mivacurium: A new muscle relaxant compared with atracurium and vecuronium [in German]. Anaesthesiol Reanim 1997; 22:95-9
26. Trankle C, Kostenis E, Mohr K: Muscarinic allosteric modulation: M2/M3 subtype selectivity of gallamine is independent of G-protein coupling specificity. Naunyn Schmiedebergs Arch Pharmacol 2001; 364:172-8
27. Michel AD, Delmendo RE, Lopez M, Whiting RL: On the interaction of gallamine with muscarinic receptor subtypes. Eur J Pharmacol 1990; 182:335-45
28. Lee AM, Jacoby DB, Fryer AD: Selective muscarinic receptor antagonists for airway diseases. Curr Opin Pharmacol 2001; 1:223-9
29. Emala CW, Aryana A, Levine MA, Yasuda RP, Satkus SA, Wolfe BB, Hirshman CA: Basenji-greyhound dog: Increased m2 muscarinic receptor expression in trachealis muscle. Am J Physiol 1995; 268:L935-40
30. Vettermann J, Beck KC, Lindahl SG, Brichant JF, Rehder K: Actions of enflurane, isoflurane, vecuronium, atracurium and pancuronium on pulmonary resistance in dogs. ANESTHESIOLOGY 1988; 69:688-95
31. Lazareno S, Popham A, Birdsall NJ: Progress toward a high-affinity allosteric enhancer at muscarinic M1 receptors. J Mol Neurosci 2003; 20:363-7
32. Ellis J, Huyler J, Brann MR: Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 1991; 42:1927-32
33. Lammers JW, Minette P, McCusker M, Barnes PJ: The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in humans. Am Rev Resp Dis 1989; 139:446-9
34. Ukena D, Wehinger C, Engelstatter R, Steinijans V, Sybrecht GW: The muscarinic M1-receptor-selective antagonist, telenzepine, had no bronchodilatory effects in COPD patients. Eur Resp J 1993; 6:378-82
35. Cazzola M, Matera MG, Liccardi G, Sacerdoti G, D'Amato G, Rossi F: Effect of telenzepine, an M1-selective muscarinic receptor antagonist, in patients with nocturnal asthma. Pulm Pharmacol 1994; 7:91-7
36. Olszewski MA, Zhang XY, Robinson NE: Pre- and postjunctional effects of inflammatory mediators in horse airways. Am J Physiol 1999; 277:L327-33
37. Xu C, Michelsen KA, Wu M, Morozova E, Panula P, Alreja M: Histamine innervation and activation of septohippocampal GABAergic neurones: Involvement of local ACh release. J Physiol 2004; 561:657-70
38. Eltze M, Mutschler E, Lambrecht G: Affinity profiles of pizotifen, ketotifen and other tricyclic antimuscarinics at muscarinic receptor subtypes M1, M2 and M3. Eur J Pharmacol 1992; 211:283-93
39. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: Focus on newer generation compounds. Psychopharmacology (Berl) 1994; 114:559-65
40. Goudsouzian NG: Rapacuronium and bronchospasm. ANESTHESIOLOGY 2001; 94:727-8
41. Adams C: Anesthesia drug is being pulled from market after five deaths. The Wall Street Journal 2001; B3
42. Kron SS: Severe bronchospasm and desaturation in a child associated with rapacuronium. ANESTHESIOLOGY 2001; 94:923-4
43. Naguib M: How serious is the bronchospasm induced by rapacuronium? ANESTHESIOLOGY 2001; 94:924-5
44. Meakin GH, Pronske EH, Lerman J, Orr R, Joffe D, Savaree AM, Lynn AM: Bronchospasm after rapacuronium in infants and children. ANESTHESIOLOGY 2001; 94:926-7
45. Orzechowski RF, Currie DS, Valancius CA: Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models. Eur J Pharmacol 2005; 506:257-64
46. Howell G III, West L, Jenkins C, Lineberry B, Yokum D, Rockhold R: In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine. BMC Pharmacol 2005; 5:13
47. Liu H, Farley JM: Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport. BMC Pharmacol 2005; 5:8
48. Tobias JD, Johnson JO, Sprague K, Johnson G: Effects of rapacuronium on respiratory function during general anesthesia: A comparison with cis-atracurium. ANESTHESIOLOGY 2001; 95:908-12
49. Fine GF, Motoyama EK, Brandom BW, Fertal KM, Mutich R, Davis PJ: The effect on lung mechanics in anesthetized children with rapacuronium: A comparative study with mivacurium. Anesth Analg 2002; 95:56-61
50. Levy JH, Pitts M, Thanopoulos A, Szlam F, Bastian R, Kim J: The effects of rapacuronium on histamine release and hemodynamics in adult patients undergoing general anesthesia. Anesth Analg 1999; 89:290-5
51. Hou VY, Hirshman CA, Emala CW: Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors. ANESTHESIOLOGY 1998; 88:744-50
52. Stockton JM, Birdsall NJ, Burgen AS, Hulme EC: Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 1983; 23:551-7
53. Waelbroeck M: Identification of drugs competing with d-tubocurarine for an allosteric site on cardiac muscarinic receptors. Mol Pharmacol 1994; 46: 685-92
54. Lazareno S, Gharagozloo P, Kuonen D, Popham A, Birdsall NJ: Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: Radioligand binding studies. Mol Pharmacol 1998; 53:573-89
55. Krejci A, Tucek S: Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Mol Pharmacol 2001; 60:761-7
56. Lazareno S, Birdsall NJ: Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 1995; 48:362-78
57. Jakubik J, Bacakova L, el Fakahany EE, Tucek S: Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 1997; 52:172-9
58. Heerdt PM, Kang R, The A, Hashim M, Mook RJ Jr, Savarese JJ: Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430A) in dogs. ANESTHESIOLOGY 2004; 100:846-51
59. Belmont MR, Lien CA, Tjan J, Bradley E, Stein B, Patel SS, Savarese JJ: Clinical pharmacology of GW280430A in humans. ANESTHESIOLOGY 2004; 100:768-73
60. Savarese JJ, Belmont MR, Hashim MA, Mook RA Jr, Boros EE, Samano V, Patel SS, Feldman PL, Schultz JA, McNulty M, Spitzer T, Cohn DL, Morgan P, Wastila WB: Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: A comparison with mivacurium. ANESTHESIOLOGY 2004; 100:835-45